Total Payments
$36,679
2024 Payments
$4,277
Companies
103
Transactions
1,058
Medicare Patients
4,396
Medicare Billing
$2.5M
Payment Breakdown by Category
Food & Beverage$23,297 (63.5%)
Consulting$8,231 (22.4%)
Education$2,493 (6.8%)
Other$1,814 (4.9%)
Gifts$629.43 (1.7%)
Travel$215.18 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $23,297 | 988 | 63.5% |
| Consulting Fee | $8,231 | 5 | 22.4% |
| Education | $2,493 | 37 | 6.8% |
| Long term medical supply or device loan | $1,814 | 19 | 4.9% |
| Gift | $629.43 | 5 | 1.7% |
| Travel and Lodging | $215.18 | 4 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,539 | 80 | $0 (2024) |
| Janssen Biotech, Inc. | $3,535 | 50 | $0 (2024) |
| TESARO, Inc. | $3,115 | 11 | $0 (2019) |
| Celgene Corporation | $2,243 | 24 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $2,047 | 23 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,455 | 54 | $0 (2024) |
| GENZYME CORPORATION | $1,235 | 44 | $0 (2024) |
| PFIZER INC. | $1,155 | 70 | $0 (2024) |
| Astellas Pharma US Inc | $1,117 | 31 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,114 | 62 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,277 | 157 | Janssen Biotech, Inc. ($309.98) |
| 2023 | $5,854 | 172 | Novartis Pharmaceuticals Corporation ($598.31) |
| 2022 | $4,970 | 168 | Novartis Pharmaceuticals Corporation ($596.66) |
| 2021 | $4,249 | 151 | Novartis Pharmaceuticals Corporation ($1,139) |
| 2020 | $3,760 | 73 | Celgene Corporation ($1,750) |
| 2019 | $6,597 | 91 | TESARO, Inc. ($3,030) |
| 2018 | $4,415 | 103 | Janssen Biotech, Inc. ($2,479) |
| 2017 | $2,557 | 143 | E.R. Squibb & Sons, L.L.C. ($380.85) |
All Payment Transactions
1,058 individual payment records from CMS Open Payments — Page 1 of 43
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $26.38 | General |
| Category: NONE | ||||||
| 12/19/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $34.10 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/17/2024 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Food and Beverage | In-kind items and services | $22.61 | General |
| Category: Hematology | ||||||
| 12/17/2024 | Geron Corporation | RYTELO (Drug) | Food and Beverage | In-kind items and services | $18.73 | General |
| Category: MYELODYSPLASTIC SYNDROME | ||||||
| 12/16/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $37.69 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $28.38 | General |
| Category: Hematology/Oncology | ||||||
| 12/11/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $0.82 | General |
| Category: Hematology/Oncology | ||||||
| 12/10/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Food and Beverage | In-kind items and services | $145.99 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $25.40 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Food and Beverage | In-kind items and services | $18.97 | General |
| Category: Oncology | ||||||
| 12/06/2024 | SOBI, INC | DOPTELET (Drug) | Education | In-kind items and services | $99.95 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/06/2024 | SOBI, INC | SYNAGIS (Drug) | Food and Beverage | In-kind items and services | $15.68 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | ARRAY BIOPHARMA INC | XALKORI (Drug), LORBRENA, BRAFTOVI | Food and Beverage | In-kind items and services | $26.39 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $18.06 | General |
| Category: ONCOLOGY | ||||||
| 12/03/2024 | Amneal Pharmaceuticals LLC | AVASTIN (Drug) | Food and Beverage | In-kind items and services | $27.37 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $17.63 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 11/27/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $19.38 | General |
| Category: Oncology | ||||||
| 11/25/2024 | Incyte Corporation | MONJUVI (Drug) | Food and Beverage | Cash or cash equivalent | $27.59 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $22.47 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Food and Beverage | In-kind items and services | $22.92 | General |
| Category: Hematology | ||||||
| 11/19/2024 | SOBI, INC | SYNAGIS (Drug) | Food and Beverage | In-kind items and services | $15.28 | General |
| Category: IMMUNOLOGY | ||||||
| 11/18/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $25.41 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $19.86 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/13/2024 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug), Vitrakvi, Nubeqa | Food and Beverage | In-kind items and services | $24.82 | General |
| Category: Oncology | ||||||
| 11/06/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $19.97 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 1,069 | 42,365 | $1.9M | $1.1M |
| 2022 | 22 | 994 | 43,322 | $729,154 | $321,061 |
| 2021 | 24 | 1,143 | 55,714 | $1.6M | $912,418 |
| 2020 | 25 | 1,190 | 28,069 | $499,348 | $213,049 |
Total Patients
4,396
Total Services
169,470
Medicare Billing
$2.5M
Procedure Codes
92
All Medicare Procedures & Services
92 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 11 | 18,000 | $1.1M | $681,705 | 63.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 17 | 7,380 | $271,200 | $132,979 | 49.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 196 | 1,053 | $210,600 | $103,577 | 49.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 39 | 396 | $132,660 | $42,202 | 31.8% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 16 | 1,800 | $63,000 | $29,621 | 47.0% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 42 | 753 | $64,005 | $18,230 | 28.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 182 | 903 | $10,836 | $7,476 | 69.0% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 14 | 125 | $17,500 | $6,794 | 38.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 182 | 902 | $18,040 | $6,766 | 37.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 45 | 103 | $15,450 | $5,570 | 36.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 36 | 36 | $12,600 | $4,278 | 34.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 29 | 35 | $6,125 | $3,416 | 55.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 17 | 46 | $6,900 | $2,984 | 43.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 20 | 40 | $6,000 | $2,846 | 47.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 55 | 234 | $10,530 | $2,724 | 25.9% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 17 | 85 | $2,125 | $584.70 | 27.5% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 37 | 5,815 | $5,815 | $567.30 | 9.8% |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | Office | 2023 | 34 | 4,294 | $4,294 | $326.96 | 7.6% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 34 | 83 | $415.00 | $98.75 | 23.8% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2023 | 29 | 180 | $900.00 | $86.46 | 9.6% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 17 | 102 | $306.00 | $84.78 | 27.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 22 | 7,501 | $240,035 | $125,631 | 52.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 199 | 870 | $172,100 | $87,062 | 50.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 37 | 376 | $125,960 | $42,331 | 33.6% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2022 | 16 | 23,251 | $46,502 | $20,629 | 44.4% |
About Dr. Rene Rubin, MD
Dr. Rene Rubin, MD is a Hematology & Oncology healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/14/2005. The National Provider Identifier (NPI) number assigned to this provider is 1285633016.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rene Rubin, MD has received a total of $36,679 in payments from pharmaceutical and medical device companies, with $4,277 received in 2024. These payments were reported across 1,058 transactions from 103 companies. The most common payment nature is "Food and Beverage" ($23,297).
As a Medicare-enrolled provider, Rubin has provided services to 4,396 Medicare beneficiaries, totaling 169,470 services with total Medicare billing of $2.5M. Data is available for 4 years (2020–2023), covering 92 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Philadelphia, PA
- Active Since 07/14/2005
- Last Updated 10/03/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1285633016
Products in Payments
- ZEJULA (Drug) $3,224
- KISQALI (Drug) $2,572
- IMBRUVICA (Drug) $2,026
- Pomalyst (Drug) $1,974
- Vitrakvi (Drug) $1,674
- DARZALEX (Biological) $1,542
- OPDIVO (Biological) $899.15
- JEVTANA (Drug) $735.94
- KEYTRUDA (Biological) $601.50
- IBRANCE (Drug) $512.00
- VENCLEXTA (Drug) $467.27
- Lenvima (Drug) $466.24
- ERLEADA (Drug) $458.25
- CABOMETYX (Drug) $442.90
- JAKAFI (Drug) $429.30
- SARCLISA (Biological) $380.16
- ENHERTU (Drug) $340.49
- Kyprolis (Drug) $339.76
- PADCEV (Biological) $315.48
- MONOFERRIC (Drug) $311.78
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Philadelphia
Shayma Kazmi, Md, MD
Hematology & Oncology — Payments: $715,210
Hematology & Oncology $715,210
Charu Aggarwal, Md, Mph, MD, MPH
Hematology & Oncology — Payments: $510,275
Hematology & Oncology $510,275
Dr. Catherine Lai, M.d., M.p.h, M.D., M.P.H
Hematology & Oncology — Payments: $249,951
Hematology & Oncology $249,951
Dr. Martin Edelman, M.d, M.D
Hematology & Oncology — Payments: $207,464
Hematology & Oncology $207,464
Keith Pratz, M.d, M.D
Hematology & Oncology — Payments: $175,955
Hematology & Oncology $175,955
David Porter, Md, MD
Hematology & Oncology — Payments: $173,636
Hematology & Oncology $173,636